Scinai Immunotherapeutics Licenses VAX-24 Flu Vaccine
Ticker: SCNI · Form: 6-K · Filed: 2025-03-24T00:00:00.000Z
Sentiment: neutral
Topics: licensing-agreement, vaccine-candidate, update
TL;DR
Scinai licensed its VAX-24 flu vaccine to a US company on Sept 26, 2024.
AI Summary
On September 26, 2024, Scinai Immunotherapeutics Ltd. granted exclusive global rights to its VAX-24 influenza vaccine candidate to an unaffiliated U.S. private company, referred to as the "Licensee." This 6-K filing provides an update on this licensing agreement, which was previously disclosed.
Why It Matters
This licensing agreement allows Scinai to potentially monetize its VAX-24 asset while focusing on other pipeline developments, impacting its future revenue streams and strategic direction.
Risk Assessment
Risk Level: low — This filing is an update on a previously disclosed licensing agreement and does not introduce new material risks.
Key Players & Entities
- Scinai Immunotherapeutics Ltd. (company) — Registrant and licensor of VAX-24
- VAX-24 (product) — Influenza vaccine candidate licensed to Licensee
- Licensee (company) — Unaffiliated U.S. private company that received exclusive rights to VAX-24
- September 26, 2024 (date) — Date the license agreement was entered into
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose is to provide an update on the previously disclosed license agreement entered into on September 26, 2024, between Scinai Immunotherapeutics Ltd. and an unaffiliated U.S. private company for the VAX-24 influenza vaccine candidate.
Who is the counterparty to the license agreement for VAX-24?
The counterparty is an unaffiliated U.S. private company referred to as the "Licensee."
What rights were granted under the license agreement?
Scinai Immunotherapeutics Ltd. granted exclusive global rights to its VAX-24 influenza vaccine candidate to the Licensee.
When was the license agreement originally entered into?
The license agreement was entered into on September 26, 2024.
Does this filing indicate any new financial terms or milestones related to the VAX-24 license?
This filing does not specify any new financial terms or milestones; it serves as an update on the existence and nature of the previously disclosed licensing agreement.
From the Filing
0001013762-25-001666.txt : 20250324 0001013762-25-001666.hdr.sgml : 20250324 20250324171047 ACCESSION NUMBER: 0001013762-25-001666 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250324 FILED AS OF DATE: 20250324 DATE AS OF CHANGE: 20250324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 25765036 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0235501-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of March 2025 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Explanatory Note As previously disclosed, on September 26, 2024, Scinai Immunotherapeutics Ltd. (“Scinai”) entered into a license agreement with an unaffiliated U.S. private company (“Licensee”), pursuant to which Scinai has granted Licensee exclusive global rights to certain patents and know-how under Scinai’s agreement with the Max Planck Society and the University Medical Center Göttingen for the development and commercialization of licensed products. Information communicated to the Company indicates the Licensee has determined that current market conditions and capital resources available to the Licensee make it inadvisable to proceed at this time with the remainder of the pre-clinical evaluation and, accordingly, has exercised its right to terminate the agreement. This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344 ) and Form F-3 (File No. 333-274078 and File No. 333-276767 ), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Scinai Immunotherapeutics Ltd. Date: March 24, 2025 By: /s/ Amir Reichman Amir Reichman Chief Executive Officer 2